Article Text

other Versions

PDF
Budesonide improves decreased airway conductance in infants with respiratory symptoms
  1. Anna S Pelkonen (anna.pelkonen{at}hus.fi)
  1. Helsinki University Central Hospital, Finland
    1. Kristiina Malmström
    1. Helsinki University Central Hospital, Finland
      1. L Pekka Malmberg
      1. Helsinki University Central Hospital, Finland
        1. Seppo Sarna
        1. University of Helsinki, Finland
          1. Markku Turpeinen
          1. Helsinki University Central Hospital, Finland
            1. Merja Kajosaari
            1. Helsinki University Central Hospital, Finland
              1. Tari Haahtela
              1. Helsinki University Central Hospital, Finland
                1. Mika J Mäkelä
                1. Helsinki University Central Hospital, Finland

                  Abstract

                  Objective: Inhaled corticosteroids (ICS) are commonly used to treat wheezing disorders in children but few studies have investigated the effect of ICS on lung function in infants. We evaluated the efficacy of inhaled budesonide for decreased specific airways conductance (sGaw) as an indication of bronchial obstruction in very young children with recurrent cough and/or wheeze.

                  Patient, design and interventions: Functional residual capacity (FRC) and sGaw of steroid-naive children aged 3-26 months with respiratory symptoms were measured using an infant whole-body plethysmograph. Clinically indicated bronchoscopy was performed in 79% of the patients to exclude anatomical abnormalities before randomization. Children with abnormal lung function and respiratory symptoms were randomized into two treatment groups, receiving either inhaled budesonide (400 μg/day) or placebo with Nebuchamber® for 6 weeks. Inhaled terbutaline 0.25 mg/dose was used as rescue medication. Lung function measurements were repeated after 6 weeks.

                  Main outcome measure: Lung function.

                  Results: Forty-four children, median age 11.3 months (range 3.7-25.9), completed the study. Median sGaw improved from z-score -3.6 to -1.2 (p < 0.001) in the budesonide group and from -3.2 to -2.6 (p = 0.033) in the placebo group; between group difference p=0.014. Improvement in sGaw was more pronounced in children with atopy (p = 0,017). Symptom-free days increased in both budesonide and placebo groups with no difference between the groups.

                  Conclusion: Treatment with inhaled budesonide for 6 weeks improved sGaw in young children with chronic cough or wheeze and bronchial obstruction.

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.